Sumitomo Pharma Submits an Application of Manufacturing and Marketing Authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells in Japan
On August 5, 2025, Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan) and RACTHERA Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan) announced that they have submitted an application of manufacturing and marketing authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells (INN: “raguneprocel”, hereinafter referred to as “the Product”) in Japan.
(Press release available here: https://www.sumitomo-pharma.com/news/20250805-2.html )
Nippi, Inc. (Head Office: Tokyo, Japan) has supported the development of the Product from its early stages. Laminin products, manufactured by Nippi, Inc. and marketed by its affiliate Matrixome, Inc. (Head Office: Osaka, Japan), have been utilized as a cell adhesion substrate that enables efficient maintenance, expansion, and differentiation of iPS cells.
In light of this announcement, we sincerely hope for the early approval of the Product and remain committed to providing safe and stable supplies of our laminin products.
Nippi, Inc. will continue to contribute to public health through ongoing innovation and product development.
Reference Links
Contact Information
Biological and Chemical Business Department
Email: protein-info@nippi-inc.co.jp
Homepage: Contact Form